BioCentury
ARTICLE | Clinical News

Spiriva Respimat regulatory update

February 17, 2017 4:45 PM UTC

FDA approved Spiriva Respimat tiotropium bromide from Boehringer for long-term maintenance treatment of asthma in patients ages 6-11. The drug is marketed for the indication in patients ages ≥12. Spir...